Global Ganja Report

With the DEA's rescheduling of Epidiolex, shares in the British manufacturer of the drug are soaring. But CBD—the actual cannabinoid that the product is based on—is to remain in the restrictive Scheudle 1.

As the UN General Assembly met in New York, President Trump issued a "Global Call" to renew the war on drugs—to the dismay of activists and dissenting nations. But the UN itself has a contradictory cannabis policy—with some agencies recognizing its efficacy as medicine and others backing the prohibitionist doctrine of the Single Convention treaty.

Among several cannabis-related bills that cleared California's state house before the last legislative session came to close is one that would lift the tax burden on medical marijuana providers. The bill is intended to again open space for "compassionate care," which was ironically squeezed out under California's adult-use regulation regime. 

Having just undertaken a "critical study" of CBD, the non-psychoactive cannabinoid held to have multifarious medicinal applications, the World Health Organization is now opening such a study on THC. Stigmatized due to its psychoactive properties and currently in the shadow of the suddenly sexy CBD, tetrahydrocannabinol shows its own potential for application by the medical industry.

The British government has finally capitulated to pressure from patients, activists and even regional authorities, and officially pledged to make medical cannabis products available on prescription this year. But it remains to be seen which products will win approval—and actual herbaceous cannabis is unlikely to make the cut.

California health authorities dealt a blow to the burgeoning CBD business by banning preparations of the cannabinoid derived from industrial hemp rather than psychoactive cannabis. The diktat adds to the legal confusion around CBD, and highlights the need for greater clarity from the competent authorities at both the state and federal level.

A federal appeals court has turned down a challenge by the cannabis industry to the DEA's official finding that CBD is a controlled substance. But questions about whether CBD should be treated as a controlled substance remain pending at the state level.

A judge for the US District Court for the Southern District of New York on Feb. 26 dismissed a lawsuit challenging the Schedule I classification for cannabis under the Controlled Substances Act. Judge Alvin Hellerstein granted the government's motion to dismiss because the plaintiffs failed to exhaust all administrative remedies prior to initiating the suit. The "exhaustion rule" requires "that parties exhaust prescribed administrative remedies before seeking relief from federal courts."